Instructions Protargol ear and nasal drops 2% bottle 10 ml
Composition
active ingredient: argenti proteinas;
100 g of solution contains 2 g of silver proteinate;
excipients: disodium hydrogen phosphate, potassium dihydrogen phosphate, imidourea, purified water.
Dosage form
Nasal/ear drops, 2% solution.
Main physicochemical properties: brown solution with slight opalescence.
Pharmacotherapeutic group
Means used in diseases of the nose. Anti-edematous and other means for local use in diseases of the nose. Other means for the treatment of diseases of the nose. ATX code R01A X10.
Pharmacological properties
Pharmacodynamics
Antibacterial agent. Silver proteinate, silver ion, or silver salt preparations inhibit the growth of gram-positive and gram-negative bacteria (bacteriostatic action). In addition, silver ions determine the precipitation of bacterial proteins (bactericidal action).
Pharmacokinetics
Silver proteinate applied topically is poorly absorbed.
Indication
Decongestant and antiseptic for the nasal mucosa and antiseptic for the ear canal.
Contraindication
Hypersensitivity to any substance included in the medicinal product.
Interaction with other medicinal products and other types of interactions
Protargol may interact with drugs that contain papain.
Papain is a proteolytic enzyme belonging to the class of hydrolases extracted from unripe papaya fruits (Carica papaya).
Simultaneous use of silver proteinate and papain may reduce the enzymatic action of the latter.
Application features
Avoid simultaneous use with papaya-based preparations (see section "Interaction with other medicinal products and other types of interactions"). The recommended doses and method of administration of the drug should be followed. Silver proteinate, if used excessively over a long period of time, may cause toxic effects.
Use during pregnancy or breastfeeding
Pregnancy
There are insufficient data on the use of silver proteinate in pregnant women. Silver proteinate should not be used during pregnancy unless clearly necessary.
Breast-feeding
There is insufficient data on the use of silver proteinate during breastfeeding. Silver proteinate should not be used during breastfeeding unless clearly necessary.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Method of administration and doses
Instill 1–2 drops into each nostril or ear canal 2–3 times a day. The course of treatment is 5–10 days.
Children
The medicine is not intended for use in children.
Overdose
In case of overdose, which is associated with the accumulation of high concentrations of silver ions in the blood plasma, skin discoloration and slurred speech may occur. Accumulation of silver in the skin, mucous membranes, membranes and eyes, which is associated with prolonged use of the drug, may cause allergies, a characteristic feature of which is the coloring of the skin from gray to dark blue, which is caused by the interaction of silver with various proteins and, as a result, the production of pigments. In addition, systemic symptoms such as hepatotoxicity, cardiomyopathy, amnesia may occur, which are a consequence of the neurotoxic process.
Adverse reactions
Data on the frequency of individual listed effects are not provided.
Skin and subcutaneous tissue disorders: dermatitis, rash, heartburn, skin irritation, skin discoloration, hypersensitivity reactions, allergy.
Expiration date
2 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children. Shelf life after opening the package is 15 days.
Packaging
10 ml in a glass bottle with a pipette cap; 1 bottle in a cardboard box.
Vacation category
Without a prescription.
Producer
Chemical and Pharmaceutical Laboratory "A. Sella" s.r.l.
Location of the manufacturer and address of its place of business
Via Vicenza, 67, 36015-Schio (VI), Italy.
